White Papers
Sterile Formulation Strategies to Shorten Timelines for First-in-Human Studies
On the long and costly path to market, early development decisions that prepare a molecule for its clinical journey are among the most critical.
sartorius-live-cell-monitoring-advanced-cell-models-whitepaper
Advanced cell models such as organoids, spheroids, stem cells, and iPSC-derived systems are transforming biomedical research, drug discovery, and regenerative medicine.
Building a unified design-make-test-decide approach to drug discovery
Drug discovery has long followed a core loop: design a molecule, synthesize it, test its biological properties, and analyze the results to inform the next round of design.
Beyond algorithms: Building stronger AI foundations for drug discovery
Modern drug discovery produces more data than ever, from genomics and chemical screening to imaging and patient datasets
Leading the Way in Biotech Solutions Across JAPAC
Are you a U.S. biotech company struggling with patient recruitment, prolonged study timelines, rising costs, or unlocking the full value of your asset in key markets such as Japan or China
The benefits of 5,000L singleuse bioreactors for biologics manufacturing
The market for complex biologics including monoclonal antibodies, bispecific antibodies and fusion molecules is growing at a rapid pace.
Quantifying the ROI of Integrated CDMO-CRO Models in Drug Development
As development costs climb and project timelines grow tighter, the traditional outsourcing model is showing its limitations.
Unlock Faster, More Confident Biosimilar Development
Developing biosimilars requires rigorous analytical characterization to ensure safety, efficacy, and regulatory approval.
Master Measurement Uncertainty in Laboratory Weighing
Every laboratory measurement carries some level of uncertainty—but in regulated environments, uncontrolled variation can compromise compliance, data integrity, and research outcomes.
Unlock Smarter Lifecycle Strategies for Injectable Therapeutics
As the injectable drug market continues to expand - driven by the rise of biologics, biosimilars, and patient-centric therapies-pharmaceutical companies face increasing pressure to differentiate their products, reduce costs, and optimize delivery systems.
